|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Tumor Biology |
Department of Neurosurgery, Neurological Institute, Faculty of Medicine, Kyushu University, Fakuoka, 812-8582 Japan (M.M., T.I., T.S., K.I., S.I., M.F.); and Department of Neurosurgery, Hamanomachi Hospital, Fukuoka, 810-8539 Japan (S.O.)
2 Address correspondence and reprint requests to Takanori Inamura, Department of Neurosurgery, Neurological Institute, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Abstract
Intracranial germinoma has a relatively good prognosis when treated with radiotherapy and chemotherapy, whereas glioblastoma has a poor prognosis irrespective of these treatments. Cell proliferation and cell death are opposing processes in tumor growth, with tumor progression reflecting the balance between proliferating and apoptotic cells. We investigated cell proliferation and cell death using MIB-1 staining and nick-end labeling in 13 germinomas in comparison with 11 glioblastomas. Expression of BAX and Bcl-2, which regulate apoptosis, were studied by immunohistochemistry. Although germinomas showed strong MIB-1 immunostaining similar to that seen in glioblastomas, germinomas included significantly more apoptotic cells. The ratio of apoptotic ratio to MIB-1 labeling index for germinomas was 72.9 ± 36.9 (mean ± SD), a higher, statistically significant ratio as compared with glioblastomas (14.5 ± 11.2; P < 0.01). Furthermore, germinomas showed greater expression of BAX than did glioblastomas, while the expression of Bcl-2 was weak in both tumor types. A comparison of these apoptotic-related proteins showed that immunoreactivity for BAX was relatively higher in germinomas than in glioblastomas (P < 0.01), corresponding well to numerous apoptotic cells identified in germinoma tissues. These findings may account for the prognostic difference between germinoma and glioblastoma in the face of a similar proliferation potential according to MIB-1 immunostaining. The balance between cell proliferation and death should be considered when predicting outcomes in patients with intracranial tumors.
References
Alderson, L.M., Castleberg, R.L., Harsh, G.R., IV, Louis, D.N., and
Henson, J.W. (1995) Human gliomas with wild-type p53 express
bcl-2. Cancer Res. 55,999
-1001.
Allan, D.J., Howell, A., Roberts, S.A., Williams, G.T., Watson, R.J., Coyne, J.D., Clarke, R.B., Laidlaw, I.J., and Potten, C.S. (1992) Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. J. Pathol. 167, 25-32.[CrossRef][ISI][Medline]
Belloma, G., Perotti, M., Taddei, F., Mirabelli, F., Finardi, G.,
Nicotera, P, and Orrenius, S. (1992) Tumor necrosis factor alpha
induces apoptosis in mammary adenocarcinoma cells by an increase in
intracellular free Ca2+ concentration and DNA fragmentation.
Cancer Res. 52,1342
-1346.
Clarke, A.R., Purdie, C.A., Harrison, D.J., Morris, R.G., Bird, C.C., Hooper, M.L., and Wyllie, A.H. (1993) Thymocyte apoptosis induced by p53 dependent and independent pathways. Nature 362,849 -852.[CrossRef][Medline]
Cunningham, J.M., Kimmel, D.W., Scheithauer, B.W., O'Fallon, J.R., Novotny, P.J., and Jenkins, RB. (1997) Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationships and prognostic value. J. Neurosurg. 86,121 -130.[ISI][Medline]
Gavrieli, Y., Sherman, Y., and Ben-Sasson, S.A. (1992)
Identification of programmed cell death in situ via specific labeling of
nuclear DNA fragmentation. J. Cell Biol.
119,493
-501.
Kordek, R., Hironishi, M., Liberski, P.P., Yanagihara, R., and Gajdusek, D.C. (1996) Apoptosis in glial tumors as determined by in situ nonradioactive labeling of DNA breaks. Acta. Neuropathol. (Berl.) 91,112 -116.[Medline]
Krajewski, S., Krajewska, M., Ehrmann, J., Sikorska, M., Lach, B., Chatten, J., and Reed, J.C. (1997) Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am. J. Pathol. 50,805 -814.
Krishna, M., Smith, T.W., and Recht, L.D. (1995) Expression of bcl-2 in reactive and neoplastic astrocytes: Lack of correlation with presence or degree of malignancy. J. Neurosurg. 83,1017 -1022.[Medline]
Matsutani, M., Sano, K., Takakura, K., Fujimaki, T., Nakamura, O., Funata, N., and Seto, T. (1997) Primary intracranial germ cell tumors: A clinical analysis of 153 histologically verified cases. J. Neurosurg. 86,446 -455.[ISI][Medline]
Oltvai, Z.N., Milliman, C.L., and Korsmeyer, S.J. (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74,609 -619.[CrossRef][ISI][Medline]
Onda, K., Davis, R.L., and Edwards, M.S. (1996) Comparison of bromodeoxyuridine uptake and MIB 1 immunoreactivity in medulloblastomas determined with single and double immunohistochemical staining methods. J. Neurooncol. 29,129 -136.[Medline]
Patsouris, E., Davaki, P., Kapranos, N., Davaris, P., and Papageorgiou, K. (1996) A study of apoptosis in brain tumors by in situ end-labeling method. Clin. Neuropathol. 15,337 -341.[Medline]
Reed, J.C. (1994) Mini-Review: Cellular mechanisms of disease series: Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 24,1 -6.
Reeve, J.G, Xiong, J., Morgan, J., and Bleehen, N.M. (1996) Expression of apoptosis-regulatory genes in lung tumour cell lines: Relationship to p53 expression and relevance to acquired drug resistance. Br. J. Cancer 73,1193 -1200.[ISI][Medline]
Rieger, L., Weller, M., Bornemann, A., Schabet, M., Dichgans, J., and Meyermann, R. (1998) BCL-2 family protein expression in human malignant glioma: A clinical-pathological correlative study. J. Neurol. Sci. 155,68 -75.[CrossRef][Medline]
Sakakura, C., Sweeney, E.A., Shirahama, T., Igarashi, Y., Hakomori, S., Nakatani, H., Tsugimoto, H., Imanishi, T., Ohgaki, M., Ohyama, T., Yamazaki, J., Hagiwara, A., Yamaguchi, T., Sawai, K., and Takahashi, T. (1996) Overexpression of Bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int. J. Cancer 67,101 -105.[CrossRef][ISI][Medline]
Sallinen, P.K., Haapasalo, H.K., Visakorpi, T., Helen, P.T., Rantala, I.S., Isola, J.J., and Helin, H.J. (1994) Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J. Pathol. 174,275 -282.[CrossRef][ISI][Medline]
Shapiro, W.R., Green, S.B., Burger, P.C., Mahaley, M.S., Jr., Selker, R.G., VanGilder, J.C., Robertson, J.T., Ransohoff, J., Mealey, J., Jr., Strike, T.A., and Pistenmaa, D.A. (1989) Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma: Brain Tumor Cooperative Group Trial 8001. J. Neurosurg. 71,1 -9.[ISI][Medline]
Shibuya, M., Ito, S., Miwa, T., Davis, R.L., Wilson, C.B., and Hoshino, T. (1993) Proliferative potential of brain tumors: Analyses with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nuclear organizer region counts. Cancer 71,199 -206.[CrossRef][Medline]
Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., and Van Dyke, T. (1994) p53–dependent apoptosis supresses tumor growth and progression in vivo. Cell 78,703 -711.[CrossRef][ISI][Medline]
Williams, G.T. (1991) Programmed cell death: Apoptosis and oncogenesis. Cell 65,1097 -1098.[CrossRef][ISI][Medline]
Wyllie, A. (1987) Cell death. In: Bourne, G.H. (Ed.), International Review of Cytologu, supplement 17. San Diego, Calif.: Academic Press, pp.755 -785.
Yin, C., Knudson, C.M., Korsmeyer, S.J., and Van Dyke, T. (1997) Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385,637 -640.[CrossRef][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
